Replies to post #48466 on Biotech Values

[DewDiligence]

>all considered today's news was positive for IDIX<

Prior to the CC—when it was revealed that phase-3 will be delayed by a year (or more)—I would have agreed with you for the simple reason that the data met the threshold to advance the program.

But the substantial delay makes the overall news at best neutral and probably modestly negative, IMO. Speed matters, and the NM283 program just lost whatever timing lead it had relative to VRTX and VPHM.